The Cancer Therapy and Research Center at UTHSCSA
The Cancer Therapy and Research Center at UTHSCSA
San Antonio, Texas, United States3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, central nervous system cancer, neoplasm, neoplastic meningitis, nervous system disorder, tumor of meninges | Recruiting | Phase 1 / Phase 2 | 2026-09-09 | NCT07098806 | |
| Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2025-03-30 | NCT05460507 | |
| Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2025-03-26 | NCT01906385 |